🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Registration for the 5th UAE Obesity Conference is open 5uoc.info

Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease #Survodutide boehringer-ingelheim.com/human-health/m…

Bariatric surgery remains an important treatment for the disease of obesity in conjunction with nutritional therapy and pharmacotherapy libss.org/registration20…

Very important that we change the way we treat obesity and start managing it in the same way we do all other chronic diseases. Nothing more and nothing less.

Important meeting to allow us to ask ourselves why obesity should be treated no differently than any other chronic disease ➡️II KONGRES POLSKIEGO TOWARZYSTWA LECZENIA OTYŁOŚCI termedia.pl/Konferencja-II…

IRC Researcher of the Year 2023 Professor Carel le Roux collects his trophy from IRC Director Peter Brown. Many congratulations, Carel! Carel Le Roux @scienceirel UCD Research #LoveIrishResearch

👨‍🏫🏆 UCD Professor Carel Le Roux named 2023 IRC Researcher of the Year 🔹 Professor Emma Teeling ‘highly commended’ in Researcher of the Year category The Irish Research Council has named Professor Carel Le Roux Researcher of the Year for 2023. A leading clinical scientist and

Prof. Carel Le Roux and Dr. sean wharton discuss the efficacy and safety of new treatments for #obesity and explore why we have seen a shift in expectations from them. linkedin.com/posts/clinical…

EASD 2023 - Interview with Carel Le Roux about bariatric surgery and weight lowering drugs youtube.com/watch?v=VC9rB2…

Superb article by Prof Carel le Roux and Dr Alvin Mondoh analysing treatment of obesity with medications Carel Le Roux Werd Al-Najim Andy Grannell imisophia @FinianFallon ICPO tandfonline.com/doi/full/10.10…

Survodutide is an exciting new compound for the treatment of obesity. The current phase 3 studies have built on these phase 2 data showing more than 18% weight loss and several important cardiometabolic health gains sciencedirect.com/science/articl…

Patients with obesity have many barriers to treatment. The stereotype of patients with type 1 diabetes always being thin is no longer true. We need to address both diseases of obesity and type 1 diabetes imisophia onlinelibrary.wiley.com/doi/10.1111/co…

Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program link.springer.com/content/pdf/10… UCD Conway Institute

cardiacwire.com/newsletter/bio…

Carel le Roux, MD, PhD discusses building a better approach to obesity care #obesity #endocrinology #MedEd #PeerVoice peervoice.com/HPE?PromoCode=…

Let's not repeat past errors by assuming GLP-1 analogues alter food preferences without solid evidence. Verbal reports aren't enough; we need direct behavioural measures 💡➡️ link.springer.com/article/10.103…

Research recommends obesity treatment focus on health gain rather than weight loss irspen.ie/?p=7118 IrSPEN Carel Le Roux

Registration is now open for the 6TH UAE OBESITY CONFERENCE & 1ST WOF MENA CONFERENCE medicalevents.tv/cm_ups/agendas…

World Obesity Day - March 4th 2025. We call for a more patient-centered approach to the treatment of obesity.

Very excited for #IFSO2025 where Prof. Carel Le Roux will be diving into “Combined Therapies: The Dawn of a New Era” — tackling key questions in obesity treatment and how combining MBS and anti obesity medications could transform outcomes. 🩺🌍